In one of the largest health-care fraud settlements in U.S. history, Johnson & Johnson has agreed to pay $2.2 billion to resolve allegations that it had provided kickbacks to doctors and pharmacies. Federal prosecutors said that the pharmaceutical giant had particularly tried to push three of its medicines—the antipsychotic drugs Risperdal and Invega, as well as the heart drug Natrecor—and also promoted the drugs for uses not officially approved by the Food and Drug Administration. The U.S. Justice Department announced the settlement Nov. 4.
"The settlement also addresses allegations of conduct that recklessly put at risk the health of some of the most vulnerable members of our society—including young children, the elderly, and the disabled," wrote U.S. Attorney General Eric Holder in a statement.
Under the terms of the settlement, Johnson & Johnson agreed to pay $485 million in criminal fines and forfeiture, and make civil payments to federal and state governments amounting to $1.72 billion.
Idaho is set to receive $1.3 million as part of the national settlement.